Table 1 Comparisons of demographic and clinical data between migraineurs and controls

Age, years

40.6 ± 12.3

43.9 ± 12.3

0.120

Male, n (%)

46 (23.0%)

14 (34.1%)

0.132

Disease duration, years

10.2 ± 8.7

18.5 ± 11.0

-

 < 0.001

Monthly migraine attacks

3.0 ± 2.5

15.4 ± 9.0

-

 < 0.001

Monthly migraine days

3.4 ± 3.0

21.0 ± 6.2

-

 < 0.001

Peak headache pain intensity (VAS)

6.4 ± 1.1

6.9 ± 0.9

-

 < 0.05

HIT-6

49.8 ± 9.9

66.1 ± 8.1

-

 < 0.001

MIDAS

6.8 ± 8.1

16.8 ± 8.9

-

 < 0.001

PSQI

3.6 ± 2.6

13.3 ± 4.0

-

 < 0.001

HADS-D

3.5 ± 2.5

5.2 ± 2.4

-

 < 0.001

HADS-A

3.4 ± 2.6

5.4 ± 3.0

-

 < 0.001

Analgesics, n (%)

68 (47.2%)

33 (58.9%)

-

0.137

Preventive medication, n (%)

42 (29.2%)

27 (48.2%)

-

 < 0.05

Antidepressant, n (%)

9 (6.3%)

4 (7.1%)

-

0.818

Antiepileptic, n (%)

23 (16.0%)

12 (21.4%)

-

0.362

Beta-blocker, n (%)

12 (8.3%)

4 (7.1%)

-

0.781

CGRP pathway, n (%)

0

0

-

/

Lisinopril or candesartan, n (%)

2 (1.4%)

0

-

0.375

Onabotulinumtoxin A, n (%)

0

3(5.4%)

-

 < 0.05

Other, n (%)

21 (14.6%)

8 (14.3%)

0.957